Both CAFCIT® (caffeine citrate) Injection for intravenous administration and CAFCIT® (caffeine citrate) Oral Solution are clear, colorless, sterile, non-pyrogenic, preservative-free, aqueous solutions adjusted to pH 4.7. Each mL contains 20 mg caffeine citrate (equivalent to 10 mg of caffeine base) prepared in solution by the addition of 10 mg caffeine anhydrous to 5.0 mg citric acid monohydrate, 8.3 mg sodium citrate dihydrate and Water for Injection.
Caffeine, a central nervous system stimulant, is an odorless white crystalline powder or granule, with a bitter taste. It is sparingly soluble in water and ethanol at room temperature. The chemical name of caffeine is 3,7-dihydro-1,3,7-trimethyl-1 H -purine-2,6-dione. In the presence of citric acid it forms caffeine citrate salt in solution.
CAFCIT (caffeine citrate) is indicated for the short-term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age.
Media Articles Related to Cafcit (Caffeine)
Drinking more coffee may stave off multiple sclerosis
Source: Multiple Sclerosis News From Medical News Today [2016.03.04]
New research suggests drinking more coffee may help to protect against multiple sclerosis, adding to a growing body of evidence that caffeine has a neuroprotective effect.
IBS in America: survey highlights physical, social and emotional impact
Source: Irritable Bowel Syndrome News From Medical News Today [2015.12.17]
Irritable bowel syndrome (IBS) significantly impacts patients' daily lives; a new survey found symptoms can be so bothersome that many people would give up caffeine, their cell phone or internet...
Coffee linked to heart attack for persons with certain gene
Source: The Doctors Lounge - Cardiology
Persons with a genetic variation may have slower caffeine metabolism according to a study in the March 8 issue of JAMA.
Published Studies Related to Cafcit (Caffeine)
Caffeine as an adjuvant therapy to opioids in cancer pain: a randomized,
double-blind, placebo-controlled trial. 
to opioid therapy in patients with advanced cancer... CONCLUSION: Caffeine infusion significantly reduced pain and drowsiness, but the
Sumatriptan (subcutaneous route of administration) for acute migraine attacks in
CONCLUSIONS: Subcutaneous sumatriptan is effective as an abortive
Caffeine and opening the eyes have additive effects on resting arousal measures. [2011.10]
CONCLUSIONS: Caffeine and opening the eyes have additive effects on two measures of arousal, increasing SCL and reducing global EEG alpha. However, the independent variable effects are not equivalent, suggesting that one or both measures reflect additional non-arousal processes. SIGNIFICANCE: As caffeine is widely used by both children and adults, knowledge of the additivity of arousal effects of caffeine and opening the eyes is important in controlling participant state in EEG studies. The current results confirm the use of mean global alpha amplitude as a measure of resting-state arousal, but also point to non-arousal effects of visual input. Copyright (c) 2011 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
Caffeine ingestion, affect and perceived exertion during prolonged cycling. [2011.08]
Caffeine's metabolic and performance effects have been widely reported. However, caffeine's effects on affective states during prolonged exercise are unknown...
Effect of a single and repeated dose of caffeine on antigen-stimulated human natural killer cell CD69 expression after high-intensity intermittent exercise. [2011.07]
Several studies investigating the effect of caffeine on immune function following exercise have used one large bolus dose of caffeine. However, this does not model typical caffeine consumption... These findings suggest that although one large bolus dose of caffeine attenuated the exercise-induced increase in antigen-stimulated NK cell CD69 expression 1 h following strenuous intermittent exercise, this attenuation at no point fell below pre-supplement values and caffeine does not appear to depress NK cell CD69 expression.
Clinical Trials Related to Cafcit (Caffeine)
Effects of Caffeine on Intermittent Hypoxia in Infants Born Preterm [Completed]
The purpose of this pilot study is to document the extent to which intermittent hypoxia
persists beyond the age of discontinuing clinical methylxanthine, and will assess the
effect of caffeine treatment on the number of intermittent hypoxia episodes and the total
number of seconds with a hemoglobin oxygen saturation (HbO2 SAT) below 90%.
Clinical Study of Caffeine for Apnea of Prematurity [Completed]
Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers Study [Not yet recruiting]
Worldwide, liver related morbidity and mortality continue to rise. It is the 5th commonest
cause of death in the UK. Liver damage consists of two main components - a) damage to the
cells of the liver, called hepatocytes, meaning the liver cannot function properly leading
to jaundice (yellow appearance of the skin and/or eyes) and liver failure and b) scarring of
the liver, called Cirrhosis, leading to impaired function and inadequate blood flow through
the liver with potential to develop into cancer. Manifestations of this state include
ascites (fluid in the tummy) and varices (swollen blood vessels in the food pipe). Liver
transplant is currently the only curative treatment for end stage chronic liver disease.
Unfortunately its high demand has not been matched by an equivalent rise in liver donations
and even when a transplant has occurred there are numerous lifestyle effects such as
immunosuppression and kidney impairment thus outcome remains poor for many patients. Coffee
has been shown to have mortality benefit in humans and drinking two to three cups a day was
associated with a 40% reduced risk of developing cirrhosis, particularly alcohol related;
and higher the more cups consumed. Previous work has demonstrated coffee reduces the level
of fibrosis in the liver by interrupting signalling pathways, blocking the effects of
special products, called cytokines, and reducing accumulation of iron. The investigators'
hypothesis is that given the potential for caffeine to be used as a treatment in SSAO
activity associated diseases it is important to see if the activity of SSAO can be blocked
in healthy humans too. The Investigators' aim to examine the effect of caffeine on
circulating VAP-1 levels in large numbers of healthy volunteers to assess its potential as
an attractive therapeutic target in view of its low toxicity and widespread availability.
Caffeine for Apnea of Prematurity-Sleep (CAP-S) Study [Completed]
Apnea of prematurity is a common condition that is usually treated with methylxanthines.
Methylxanthines are adenosine receptor blockers that have powerful influences on the central
nervous system. However, little is known about the long-term effects of methylxanthines on
the developing brain.
The Caffeine for Apnea of Prematurity-Sleep (CAP-S) Study is a sub-study of the main
Caffeine for Apnea of Prematurity (CAP) trial, an international placebo-controlled
randomized trial of methylxanthine therapy for apnea of prematurity. This sub-study is
designed to take advantage of this cohort of ex-premature, 5-7 year old children who were
randomized at birth to receive either caffeine or placebo, and are currently receiving
detailed neurocognitive and behavioral assessments in the CAP trial.
Caffeine for Apnea of Prematurity (CAP) [Active, not recruiting]
At least 5 of every 1000 live-born babies are very premature and weigh only 500 to 1250
grams at birth. Approximately 30-40% of these high-risk infants either die or survive with
lasting disabilities. The aim of this research is to reduce this heavy burden of illness.
A multi-center randomized controlled trial has been designed in which 2000 very low birth
weight infants will be enrolled. Our goal is to determine whether the avoidance of
methylxanthine drugs will improve survival without disability to 18 months, corrected for
Methylxanthine drugs such as caffeine are used to prevent or treat periodic breathing and
breath-holding spells in premature infants. However, there is a striking lack of evidence
for the long-term efficacy and safety of this therapy. Methylxanthines block a naturally
occurring substance, called adenosine, which protects the brain during episodes of oxygen
deficiency. Such episodes are common in infants who are treated with methylxanthines. It
is possible that methylxanthines may worsen the damage caused by lack of oxygen. Therefore,
this trial will clarify whether methylxanthines cause more good than harm in very low birth